UTHR UNITED THERAPEUTICS Corp

Price (delayed)

$242.59

Market cap

$10.99B

P/E Ratio

15.9

Dividend/share

N/A

EPS

$15.26

Enterprise value

$10.98B

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and ...

Highlights
UNITED THERAPEUTICS's net income has surged by 70% YoY and by 44% QoQ
The company's EPS has surged by 67% YoY and by 44% QoQ

Key stats

What are the main financial stats of UTHR
Market
Shares outstanding
45.3M
Market cap
$10.99B
Enterprise value
$10.98B
Valuations
Price to earnings (P/E)
15.9
Price to book (P/B)
2.62
Price to sales (P/S)
6.2
EV/EBIT
12.35
EV/EBITDA
11.69
EV/Sales
6.21
Earnings
Revenue
$1.77B
EBIT
$888.8M
EBITDA
$938.7M
Free cash flow
$673.4M
Per share
EPS
$15.26
Free cash flow per share
$14.9
Book value per share
$92.54
Revenue per share
$39.12
TBVPS
$117.59
Balance sheet
Total assets
$5.36B
Total liabilities
$1.18B
Debt
$800M
Equity
$4.18B
Working capital
$2.29B
Liquidity
Debt to equity
0.19
Current ratio
8.84
Quick ratio
8.33
Net debt/EBITDA
-0.01
Margins
EBITDA margin
53.1%
Gross margin
92.9%
Net margin
38.9%
Operating margin
51.4%
Efficiency
Return on assets
13.5%
Return on equity
17.6%
Return on invested capital
19.1%
Return on capital employed
17.5%
Return on sales
50.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

UTHR stock price

How has the UNITED THERAPEUTICS stock price performed over time
Intraday
0.29%
1 week
2.95%
1 month
6.11%
1 year
29.74%
YTD
12.27%
QTD
2.95%

Financial performance

How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$1.77B
Gross profit
$1.64B
Operating income
$908.7M
Net income
$687.4M
Gross margin
92.9%
Net margin
38.9%
The operating income has soared by 151% YoY and by 63% from the previous quarter
The company's operating margin has surged by 114% YoY and by 56% QoQ
UNITED THERAPEUTICS's net income has surged by 70% YoY and by 44% QoQ
The net margin has grown by 45% YoY and by 38% from the previous quarter

Growth

What is UNITED THERAPEUTICS's growth rate over time

Valuation

What is UNITED THERAPEUTICS stock price valuation
P/E
15.9
P/B
2.62
P/S
6.2
EV/EBIT
12.35
EV/EBITDA
11.69
EV/Sales
6.21
The company's EPS has surged by 67% YoY and by 44% QoQ
The stock's P/E is 6% below its last 4 quarters average of 16.8
UTHR's price to book (P/B) is 37% higher than its 5-year quarterly average of 1.9 and 19% higher than its last 4 quarters average of 2.2
The equity has increased by 21% year-on-year and by 5% since the previous quarter
The stock's P/S is 72% above its 5-year quarterly average of 3.6 and 21% above its last 4 quarters average of 5.1
The company's revenue rose by 17% YoY and by 4.9% QoQ

Efficiency

How efficient is UNITED THERAPEUTICS business performance
The ROIC has soared by 52% YoY and by 39% from the previous quarter
UNITED THERAPEUTICS's return on assets has increased by 48% YoY and by 39% QoQ
The company's return on sales rose by 46% YoY and by 39% QoQ
The ROE has grown by 43% YoY and by 38% from the previous quarter

Dividends

What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UTHR.

Financial health

How did UNITED THERAPEUTICS financials performed over time
The quick ratio has increased by 35% year-on-year and by 20% since the previous quarter
The current ratio has grown by 33% YoY and by 16% from the previous quarter
The debt is 81% less than the equity
The equity has increased by 21% year-on-year and by 5% since the previous quarter
UNITED THERAPEUTICS's debt to equity has decreased by 17% YoY and by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.